PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
Advanced Science · 2025-07 · 12 (27)
DOI: 10.1002/advs.202501730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 08.05.2025. Verfasst von Jitong Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Wuhan, National Natural Science Foundation of China, Medical Sci-Tech innovation platform of Zhongnan Hospital.
Abstract (Originalsprache)
Advanced hepatocellular carcinoma (HCC) is characterized by poor prognosis, primarily due to limited therapeutic options and resistance to treatment. Although the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has shown promising potential, the underlying mechanisms remain inadequately understood. Here, serine/threonine‐specific protein phosphatase (PP1A) is upregulated in Lenvatinib‐resistant HCC cells and correlates with poor prognosis. Functional experiments revealed that PP1A promotes HCC progression both in vitro and in vivo. Transcriptomic analysis and ferroptosis metabolite profiling (e.g., ROS, Fe 2 ⁺, lipid‐ROS, and GSH) demonstrated that PP1A inhibits Lenvatinib‐induced ferroptosis by dephosphorylating Keap1 at site 104. This disruption of the Keap1‐Nrf2 interaction enhances the transcription of ferroptosis‐related markers and immune checkpoint PD‐L1. Notably, single‐cell sequencing and co‐culture experiments revealed that PP1A knockdown alleviates T cell exhaustion and immune evasion, thereby improving antitumor immunity. In vivo experiments further demonstrated that PP1A knockdown significantly enhances the efficacy of Lenvatinib‐ICIs combination therapy. Overall, our findings highlight PP1A as a critical regulator of ferroptosis and antitumor immunity, suggesting its potential as a predictive biomarker and therapeutic target for improving outcomes in advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, P. R. China.
- Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan, 430071, P. R. China.
- TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430071, P. R. China.
ORCID-Profile: Jitong Zhou, Weijie Ma
Förderung
- Natural Science Foundation of Wuhan
- National Natural Science Foundation of China
- Medical Sci-Tech innovation platform of Zhongnan Hospital
Zitieren
APA
Zhou, J., Gao, M., Zhang, S., Guo, W. W., He, W., Zhang, M., Chen, X., Dongzhi, C., Li, X., Yuan, Y., & Ma, W. (2025). PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. Advanced Science, 12(27). https://doi.org/10.1002/advs.202501730
Vancouver
Zhou J, Gao M, Zhang S, Guo WW, He W, Zhang M, et al. PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. Advanced Science. 2025;12(27). doi:10.1002/advs.202501730
BibTeX
@article{Zhou2025,
author = {Zhou, Jitong and Gao, Meng and Zhang, Shikun and Guo, Wing-Wa and He, Wenzhi and Zhang, Minghe and Chen, Xi and Dongzhi, Cairang and Li, Xiaomian and Yuan, Yufeng and Ma, Weijie},
title = {PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {27},
doi = {10.1002/advs.202501730}
}
EUVIMED